Sydney cancer immunotherapy research company, Imugene has presented positive vaccine trial results at the Annual American Association for Cancer Research.
The results were released after a trial period on a genetically identical mouse-model subject with HER-2+ breast cancer.
B-cell cancer growth was inhibited in the test subject after implementation of the newly developed mimitope programmed cell death protein (PD-1).
The PD-1 elicited an antibody response in the mouse that inhibited growth of the cancer tumor.
Imugene collaborated with the Medical University of Vienna at the Annual American during the trial tests.
Please read the announcement attached.
More From The Market Online
ResMed spikes on robust results and global growth spurt
ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.
- Keely Lynch
- 1 min
- 26 April 2024 13:45 (AEST)
PharmAust CEO’s sayanora triggers stock plunge
Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…
- Keely Lynch
- 1 min
- 23 April 2024 12:08 (AEST)
Unith wraps up Q1 with $5M in cash as digital humans evolve
Unith has wrapped up Q1 of 2024 with nearly $5M in cash and opex reduced. But…
- Jonathon Davidson
- 2 mins
- 24 April 2024 11:01 (AEST)
Recce wins safety board approval to dose 4g in R327 UTI infusion trial
Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…
- Jonathon Davidson
- 2 mins
- 26 April 2024 10:39 (AEST)